SETDB1 anticorps (AA 20-871)

N° du produit ABIN7871887

Cet anticorps anti-SETDB1 Polyclonal Lapin (ABIN7871887) détecte spécifiquement SETDB1 dans WB, ELISA et FACS. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour SETDB1 anticorps (AA 20-871) (ABIN7871887)

Antigène: SETDB1 (SET Domain, Bifurcated 1 (SETDB1))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp SETDB1 est non-conjugé

Application: Western Blotting (WB), ELISA, Flow Cytometry (FACS)

Détail du produit anti-SETDB1 anticorps

Épitope: AA 20-871

Fonction: SETDB1 Antibody / Histone-lysine N-methyltransferase SETDB1

Purification: Immunogen affinity purified

Immunogène: E.coli-derived human SETDB1 recombinant protein (Position: E20-E871) was used as the immunogen for the SETDB1 antibody.

Isotype: IgG

Information d'application

Indications d'application: Optimal dilution of the SETDB1 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Stock: 4 °C,-20 °C

Stockage commentaire: After reconstitution, the SETDB1 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Détails sur SETDB1

Antigène: SETDB1 (SET Domain, Bifurcated 1 (SETDB1))

Autre désignation: SETDB1

Sujet: SETDB1 antibody detects Histone-lysine N-methyltransferase SETDB1, an enzyme responsible for methylating histone H3 at lysine 9 (H3K9), a key epigenetic mark associated with transcriptional repression and heterochromatin formation. Encoded by the SETDB1 gene on chromosome 1q21.3, this nuclear protein is part of the SET domain-containing family of histone methyltransferases and plays a central role in chromatin remodeling, gene silencing, and genome stability.

SETDB1 contains a SET domain conferring methyltransferase activity, a methyl-CpG-binding domain (MBD), and a tudor domain that facilitate chromatin targeting. It forms complexes with co-repressors such as KAP1 (TRIM28) and HP1, directing H3K9 trimethylation at retroelements, developmental genes, and repetitive sequences. Through this mechanism, SETDB1 maintains transcriptional repression and contributes to X-chromosome inactivation, embryonic stem cell identity, and defense against endogenous retroviral elements.

The SETDB1 antibody is widely used in epigenetics, developmental biology, and cancer research to examine histone methylation and transcriptional silencing. Western blot analysis identifies a 170 kilodalton band corresponding to SETDB1, while immunofluorescence reveals punctate nuclear staining colocalizing with heterochromatin regions. This antibody enables researchers to assess chromatin states, epigenetic modifications, and silencing pathways across diverse cell types.

Aberrant SETDB1 expression and activity have been linked to multiple cancers, including melanoma, glioma, and lung carcinoma, where it promotes oncogenic transcriptional reprogramming and genomic instability. SETDB1 overexpression can also suppress immune responses by silencing interferon-stimulated genes. The SETDB1 antibody provides a precise reagent for studying epigenetic repression, gene regulation, and chromatin-based disease mechanisms. NSJ Bioreagents validates this antibody for its applications, ensuring high specificity for epigenetic and transcriptional research.

UniProt: Q15047